Atherosclerosis & Lipid-lowering Drugs Flashcards

1
Q

What defines if something is HDL or LDL?

A

APOPROTEINS
• A-1 = HDL
• B = LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Explain the exogenous pathways of lipid metabolism

A

When we eat food:

  1. It is broken down into chylomicrons (large)
  2. These are further broken down into FFAs + chylomicron remnants
  3. Chylomicron remnants –> deposit in vessels –> atheroma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Explain the endogenous pathways

A

MOST HDL/LDL comes from this pathway
• Lipoprotein lipase & Hepatic lipase metabolise the most
• IDL & LDLS are deposited in vessels to form atheromas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain what is meant by ‘Reverse Cholesterol Transport’

A

The REMOVAL of cholesterol from VESSEL WALLS

back to the liver by HDL!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define atherosclerosis

A

An inflammatory fibro-proliferative disorder

Remnant cholesterol is PRO-inflammatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

8 general steps that leads to atherosclerosis?

A
  1. LDL enters endothelium (into tunica intima (media is VSMCs))
  2. LDLs are oxidised by macrophages and VSMCs
  3. Release of growth factors and cytokines
  4. Additional monocytes/macrophages recruited
  5. Foam cell accumulation (macrophages that contain lots of lipids)
  6. VSMC migration
  7. VSMC proliferation
  8. Plaque growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Explain the ‘Endothelial Dysfunction’ part of Atherosclerosis

A
It is characterised by:
	Increased endothelial permeability
	Upregulation of adhesion molecules
	Leucocyte adhesion
	Migration of leucocytes into artery wall
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Explain the ‘Fatty Streak Formation’ of Atherosclerosis

A

The earliest recognisable lesion of atherosclerosis
• caused my FOAM CELL aggregation
- derived from macrophages & T-cells within the tunica intima
• fatty streaks usually form in the DIRECTION of BLOOD FLOW

It is characterised by:
	Migration of VSMCs (included later on)
	Activation of T-cells
	Adherence & activation of platelets
	Formation of foam cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain the ‘Plaque Formation’ of Atherosclerosis

A

It is characterised by:
 Formation of fibrous cap
- VSMCs migrate to intima & lay-down collagen fibres
- separates the lipid-rich core from circulating platelets * coagulation factors

 Accumulation of macrophages

 Formation of necrotic core
- in STABLE atherosclerotic plaques

Foam cells die & rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the different types of Atherosclerotic lesions?

A
1.	Lesion-prone location 
 – Adaptive thickening.
2.	Type 2 lesion 
 – foam cells.
3.	Type 3 lesion (preatheroma) 
 – extracellular lipid.
4.	Type 4 lesion (atheroma) 
 – bigger core of extracellular lipid.
5.	Type 5 lesion (fibroatheroma) 
 – fibrous thickening.
6.	Type 6 lesion (complicated lesion) 
 – fissure & haematoma. 

(onenote!!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What effect does remnant lipids have on the endothelium

A

The remnant lipids are the CHYLOMICRON remnants that are very good at infiltrating the endothelial wall

Remnants include:
• VLDL
• Chylomicron remnants
• IDL

Note – remnants are MORE important than LDLs here!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What causes the INFLAMMATORY part of atherosclerosis?

A

Lipid remnants!

NOT LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Charactertics of a STABLE vs. UNSTABLE plaque?

A

Stable plaque
– thick fibrous cap
– sometimes have a thinner lumen but are less likely to rupture

Unstable plaque
– thin fibrous cap
– rich core of lipids & macrophages
– less evidence of VSMC proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What normally happens if the atherosclerotic plaque is unstable?

A

Plaque
• ruptures
&
• exposes the thrombogenic lipid-rich core to circulating platelets & coagulation factors

Leads to THROMBOSIS

Note: the cell in the plaque also produces loads of factors that promotes inflammation & cause other cells to be attracted to the lesion causing:
• cells to proliferate
• plaque erosion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

LDL vs. HDL?

A

LDL
– strongly associated with atherosclerosis & CHD events
– 10% increase LDL –> 20% increase in CHD events

o These events are modified by – smoking, low HDL, hypertension & diabetes

HDL
– protective effect for atherosclerosis & CHD events

o HDL tends to be low when TG are high
o HDL is lowered by – smoking, obesity, physical inactivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drug therapies for Atherosclerosis?

A

Statins
• 1st line treatment for dyslipidaemia (effective at lowering LDL)
• good compliance

Bile Acid Sequestrants
• poor compliance (due to side-effects)

Nicotinic Acid
• effective at increasing HDL
• BUT has various SEs

Fibrates

Probucol

17
Q

Explain the MoA of statins

A

HMG-CoA Reductase inhibitors
(works on mevalonate pathways)

o This halts the cholesterol synthesis pathway.
o Halts specifically the rate-limiting step.
o Reduces the modification of proteins involved in modifying gene translation to create LDL

 This has the effect of UP-REGULATING the LDL receptors expressed on hepatocytes in the liver which results in more LDL being removed from the blood
 This also results in more HDL levels in the blood

18
Q

What else does Statin block?

A

Geranyl & Farnesyl pyrophosphate
(mevalonate pathway)
• small lipids
• important in cells as involved in modification & activation of proteins (Rho, Ras)

Cells can NOT function properly without these lipids

19
Q

What 2 things determines the different Statins properties?

A

 Selectivity ratio
– the HIGHER the selectivity ratio, the GREATER the chance of it being concentrated in the HEPATOCYTE

o	I.E. Simvastatin gets into many cells as it’s very lipid soluble. Pravastatin is mainly hepatocytes

 Potency
– the LOWER the number, the MORE POWERFUL the drug is as an inhibitor of the enzyme

20
Q

Which statin has the greatest effect?

A

Rosuvastatin

• BUT only has a modest effect in reducing TG

21
Q

What is the ‘Rule of 6’?

A

Doubling the dose (of statins) ONLY makes a 6% extra reduction

Note: ONLY with statins

22
Q

Explain the Statin Trials and the Spectrum of Risk

A

Different trials were designed to measure the effect of statins on different CHD risk groups of patients from low-risk –> high-risk
o 4S1 trial – CHD/high cholesterol group
o WOSCOPS6 – No MI/high cholesterol

Results showed that irrespective of risk group, all patients benefitted from a 30% reduction in risk

Lowered LDLs too much resulted in problems in the CNS and memory

23
Q

What is the general summary of statins use?

A

Statins can be described to have a PLEIOTROPIC effect
– both good and bad effects

Statins have multiple effects not directly related to lowering cholesterol (e.g. anti-inflammatory action)

24
Q

MoA of fibrates?

A

MoA – PPAR-alpha receptor agonist
– PPAR – Peroxisome Proliferator Activated Receptors
– Act on the liver

 Decrease FFAs and TGs.
 Increases HDL very effectively but LDL doesn’t change a lot

25
Q

What is a note to remember about fibrates?

A

NOTE: Thiazolidinediones – PPAR-GAMMA receptor agonists
o They are different!
o Act on adipose tissue.

26
Q

Explain the use of Nicotinic Acid

A

Should be very good
but
turns out in clinical practice it isn’t so not used very much.

27
Q

MoA of Ezetimibe?

A

Inhibits cholesterol ABOSPRTION

Ezetimibe –> glucuronide (in the intestines)
– ACTIVATED

Can be co-administered with statins to avoid the “rule of 6” with statins to have a more dramatic effect at lowering LDL
– shown to decrease LDL further when given w. statin

28
Q

Explain how CETP Inhibitors work

A

CETP Inhibitors – Cholesterol Ester Transfer Protein
– Torcetrapib

CETP converts HDL into LDL and so inhibiting it increases HDL levels

However, CETP inhibitors lead to lots of unexpected deaths so its use was discontinued
– possibly due to it activating aldosterone synthesis = increase in BP

29
Q

Relationship between PCSK9 & LDL receptor

A

PCSK9 is an INHIBITOR of the LDL receptor

 Monoclonal anti-PCSK9 antibodies have been made to inactivate PCSK9 and so more LDL can be absorbed by the liver
 One such group of patients that benefits from PCSK9 inhibition greatly are the people with Familial Hypercholesterolemia.